RLAY — Relay Therapeutics, Inc.

Is RLAY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Relay Therapeutics, Inc. (RLAY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $17.27. The rating moved from Neutral to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Relay Therapeutics is a pipeline-focused developer whose valuation is tied to platform execution and upcoming clinical milestones. The company benefits from a differentiated computational discovery approach and partnership optionality, but has limited revenue and relies on capital markets to fund progress. Near-term market caution and high biotech binary-event risk elevate volatility and the probability of dilution.

Key factors

  • Proprietary computational drug-discovery platform that can accelerate lead identification and create differentiation versus traditional discovery approaches
  • Pipeline-stage company profile: value driven by upcoming clinical readouts and preclinical-to-clinical progress rather than recurring revenue
  • Partnerships and licensing optionality that can de-risk programs via non-dilutive funding or milestone payments
  • Limited or no material product revenue, implying dependence on cash reserves and capital markets to fund operations
  • Current market backdrop is risk-off/defensive, which reduces appetite for small/mid-cap biotech upside in the near term
  • Biotech sector themes (large-cap pharma acquisitive activity and specialty distribution tailwinds) could create strategic exit or partnership opportunities

Risks

  • Clinical trial failures or disappointing interim readouts that materially reduce program valuations
  • High cash burn and limited runway requiring near-term equity raises that could dilute shareholders
  • Regulatory setbacks, slower-than-expected enrollment, or CMC/manufacturing issues that delay development timelines
  • Competitive risk from larger pharma/biotech entrants leveraging greater resources and established commercial channels
  • Macro and market risk: risk-off sentiment, rising rates or weak IPO/secondary market appetite impacting biotech funding
  • Lack of transparent social sentiment and no recent EDGAR comparison available increases uncertainty around investor perception and filings

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RLAY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.